Markets
Leaderboard
Gene therapy for partial vision recovery: approved by the NHS by 2025? Yes: real money 5%, play money 13% No: real money 95%, play money 87% Volume: real money 499.12532454, play money 19579.88 Bettors: real money 12, play money 39 Categories: Science, Genetics Related markets Will the US, UK or EU approve a gene editing therapy for a new condition during 2026? (ID: 239427) Volume: real 37.10543526, play 8014.42660966 Bettors: real 4, play 6 Leading (real money): Will the US, UK or EU approve a gene editing therapy for a new condition during 2026? 20% Leading (play money): Will the US, UK or EU approve a gene editing therapy for a new condition during 2026? 35% Extinct mammoth hybrids to be born alive by the end of 2027? (ID: 209130) Volume: real 67.78509857, play 11414.67183885 Bettors: real 11, play 28 Leading (real money): Extinct mammoth hybrids to be born alive by the end of 2027? 42% Leading (play money): Extinct mammoth hybrids to be born alive by the end of 2027? 15% Will the Dodo bird be de-extinct by the end of 2028? (ID: 217201) Volume: real 57.05983354, play 4175.09899414 Bettors: real 6, play 17 Leading (real money): Will the Dodo bird be de-extinct by the end of 2028? 7% Leading (play money): Will the Dodo bird be de-extinct by the end of 2028? 16%

Gene therapy for partial vision recovery: approved by the NHS by 2025?

Market Rules

Researchers at the University of Newcastle (United Kingdom) developed a kind of gene therapy that gave back the ability to recognize pictures to three patients who had lost their sight. The new technique aims to restore visual function by injecting a harmless virus that was modified to carry genetic instructions for the production - inside the patient's eye - of a protein that responds to light. The procedure allowed visual information to be transmitted to the brain when the modified cells were exposed to light.

The achievement marks an important step for optogenetics. Although still experimental, the treatment may be approved for implementation in the UK National Health Service (NHS).

If the referred therapy or any similar kind of light stimulus-associated gene therapy for partial vision recovery is approved for implementation in the NHS by the end of 2025, this market will be resolved as “Yes”.

People also viewed